Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk
BackgroundWe investigated a cross-sectional metabolomic analysis of plasma and urine of patients with early and late stage diabetes associated chronic kidney disease (CKD), inclusive of stages 1–5 CKD, to identify potential metabolomic profiles between the two groups.MethodsThis cross-sectional stud...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2022.821209/full |
| _version_ | 1828749465277693952 |
|---|---|
| author | Ashani Lecamwasam Ashani Lecamwasam Ashani Lecamwasam Toby Mansell Toby Mansell Elif I. Ekinci Elif I. Ekinci Richard Saffery Richard Saffery Karen M. Dwyer |
| author_facet | Ashani Lecamwasam Ashani Lecamwasam Ashani Lecamwasam Toby Mansell Toby Mansell Elif I. Ekinci Elif I. Ekinci Richard Saffery Richard Saffery Karen M. Dwyer |
| author_sort | Ashani Lecamwasam |
| collection | DOAJ |
| description | BackgroundWe investigated a cross-sectional metabolomic analysis of plasma and urine of patients with early and late stage diabetes associated chronic kidney disease (CKD), inclusive of stages 1–5 CKD, to identify potential metabolomic profiles between the two groups.MethodsThis cross-sectional study recruited 119 adults. Metabolomic biomarkers were quantified in 119 non-fasted plasma and 57 urine samples using a high-throughput proton Nuclear Magnetic Resonance platform. Analyses were conducted using R with the ggforestplot package. Linear regression models were minimally adjusted for age, sex, and body mass index and p-values were adjusted for multiple comparisons using the Benjamini-Hockberg method with a false discovery rate of 0.05.ResultsApolipoprotein A1 concentration (ApoA1) was reduced (adj. p = 0.04) and apolipoprotein B/apolipoprotein A1 ratio (ApoB/ApoA1) was increased (adj. p = 0.04) in late CKD compared with early CKD. Low-density lipoprotein triglyceride (LDL-TG) had an increased concentration (adj. p = 0.01), while concentrations of high-density lipoprotein cholesterol (HDL-C) were reduced (adj. p = 0.04) in late CKD compared to early stages of disease.ConclusionOur results highlight the presence of abnormal lipid metabolism namely significant reduction in the protective ApoA1 and significant increase in atherogenic ApoB/ApoA1 ratio. The study also demonstrates significantly elevated levels of triglyceride-rich lipoproteins such as LDL-TG. We illustrate the significant reduction in protective HDL-C in individuals with diabetic CKD. It explores a detailed plasma lipid profile that significantly differentiates between the late and early CKD groups as well as each CKD stage. The study of complex metabolite profiles may provide additional data required to enable more specific cardiovascular risk stratification. |
| first_indexed | 2024-12-10T20:22:19Z |
| format | Article |
| id | doaj.art-8efaa08a0e414698bbbeedba850249e7 |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-12-10T20:22:19Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-8efaa08a0e414698bbbeedba850249e72022-12-22T01:34:59ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2022-02-01910.3389/fnut.2022.821209821209Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular RiskAshani Lecamwasam0Ashani Lecamwasam1Ashani Lecamwasam2Toby Mansell3Toby Mansell4Elif I. Ekinci5Elif I. Ekinci6Richard Saffery7Richard Saffery8Karen M. Dwyer9Epigenetics Research, Murdoch Children's Research Institute, Melbourne, VIC, AustraliaDepartment of Endocrinology, Austin Health, Melbourne, VIC, AustraliaFaculty of Health, School of Medicine, Deakin University, Geelong, VIC, AustraliaEpigenetics Research, Murdoch Children's Research Institute, Melbourne, VIC, AustraliaDepartment of Paediatrics, University of Melbourne, Melbourne, VIC, AustraliaDepartment of Endocrinology, Austin Health, Melbourne, VIC, AustraliaDepartment of Medicine, University of Melbourne, Melbourne, VIC, AustraliaEpigenetics Research, Murdoch Children's Research Institute, Melbourne, VIC, AustraliaDepartment of Paediatrics, University of Melbourne, Melbourne, VIC, AustraliaFaculty of Health, School of Medicine, Deakin University, Geelong, VIC, AustraliaBackgroundWe investigated a cross-sectional metabolomic analysis of plasma and urine of patients with early and late stage diabetes associated chronic kidney disease (CKD), inclusive of stages 1–5 CKD, to identify potential metabolomic profiles between the two groups.MethodsThis cross-sectional study recruited 119 adults. Metabolomic biomarkers were quantified in 119 non-fasted plasma and 57 urine samples using a high-throughput proton Nuclear Magnetic Resonance platform. Analyses were conducted using R with the ggforestplot package. Linear regression models were minimally adjusted for age, sex, and body mass index and p-values were adjusted for multiple comparisons using the Benjamini-Hockberg method with a false discovery rate of 0.05.ResultsApolipoprotein A1 concentration (ApoA1) was reduced (adj. p = 0.04) and apolipoprotein B/apolipoprotein A1 ratio (ApoB/ApoA1) was increased (adj. p = 0.04) in late CKD compared with early CKD. Low-density lipoprotein triglyceride (LDL-TG) had an increased concentration (adj. p = 0.01), while concentrations of high-density lipoprotein cholesterol (HDL-C) were reduced (adj. p = 0.04) in late CKD compared to early stages of disease.ConclusionOur results highlight the presence of abnormal lipid metabolism namely significant reduction in the protective ApoA1 and significant increase in atherogenic ApoB/ApoA1 ratio. The study also demonstrates significantly elevated levels of triglyceride-rich lipoproteins such as LDL-TG. We illustrate the significant reduction in protective HDL-C in individuals with diabetic CKD. It explores a detailed plasma lipid profile that significantly differentiates between the late and early CKD groups as well as each CKD stage. The study of complex metabolite profiles may provide additional data required to enable more specific cardiovascular risk stratification.https://www.frontiersin.org/articles/10.3389/fnut.2022.821209/fullchronic kidney diseasediabetes mellitusmetabolomicscardiovascular disease (CVD)lipid metabolites |
| spellingShingle | Ashani Lecamwasam Ashani Lecamwasam Ashani Lecamwasam Toby Mansell Toby Mansell Elif I. Ekinci Elif I. Ekinci Richard Saffery Richard Saffery Karen M. Dwyer Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk Frontiers in Nutrition chronic kidney disease diabetes mellitus metabolomics cardiovascular disease (CVD) lipid metabolites |
| title | Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk |
| title_full | Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk |
| title_fullStr | Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk |
| title_full_unstemmed | Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk |
| title_short | Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk |
| title_sort | blood plasma metabolites in diabetes associated chronic kidney disease a focus on lipid profiles and cardiovascular risk |
| topic | chronic kidney disease diabetes mellitus metabolomics cardiovascular disease (CVD) lipid metabolites |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2022.821209/full |
| work_keys_str_mv | AT ashanilecamwasam bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT ashanilecamwasam bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT ashanilecamwasam bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT tobymansell bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT tobymansell bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT elifiekinci bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT elifiekinci bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT richardsaffery bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT richardsaffery bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk AT karenmdwyer bloodplasmametabolitesindiabetesassociatedchronickidneydiseaseafocusonlipidprofilesandcardiovascularrisk |